Pharmasset Inc. (VRUS) 29.64 +0.06

Trade VRUS
NOW!
Last Trade:29.07Short Ratio:9.80
Last Trade Time:4:00pmDay Range:28.42 - 29.18
Ask:29.64Year Range:7.69 - 29.50
Bid:27.77One Year Target:28.09
Open:28.83Exchange:NGM
Volume:731221EBITDA:-47.2M
Prev. Close:29.01Market Cap:876.6M
50 Day Moving:22.8164Div Yield:
200 day moving:21.07PE:

Buyers Accumulate Shares of Pharmasset, Up 5.3% (VRUS)

Posted on 03/17/10 at 11:36am
Pharmasset (NASDAQ: VRUS) is one of today's best performing stocks, up 5.3% to $27.83. The S&P is currently trading 1.4% higher to 1,166 and the Dow Jones Industrial Average is trading 0.8% higher to 10,730.
Click here to read the rest of the article

Benzinga’s Volume Movers (ATHN, SONC, VRUS, PETS, TWLL)

Posted on 03/16/10 at 3:22pm
athenahealth Inc (NASDAQ: ATHN) shares gained 5.28% to $39.26. The volume of ATHN shares traded was 362% higher than normal. ATHN restated its results from 2005 through the first three quarters of 2009 after the completion of the audit.
Click here to read the rest of the article
Posted in

SmarTrend's Trend Spotter See Continued Upward Momentum on Shares of Pharmasset (VRUS)

Posted on 03/16/10 at 12:54pm
SmarTrend identified an Uptrend for Pharmasset (NASDAQ: VRUS) on February 02, 2010 at $22.17. In approximately 1 month, Pharmasset has returned 20.7% as of today's recent price of $26.75.
Click here to read the rest of the article

A Peek Into Today’s Analysts Ratings (CVH, ONXX, PRXL, SBUX, WU, WYN, PSYS, UAM, VRUS)

Posted on 03/16/10 at 10:43am
Some of today’s upgrades, downgrades and initiations are: Upgrades Goldman upgraded Coventry Health (NYSE: CVH) from “sell” to “neutral.” The upgrade in the rating is based on valuation, according to Goldman. CVH’s shares lost 1.25% in after hours trading.
Click here to read the rest of the article
Posted in

Citigroup Initiates Pharmasset with a Buy; Price Target $34 (VRUS)

Posted on 03/16/10 at 10:18am
3/16/2010-Citigroup initiated coverage of Pharmasset (NASDAQ: VRUS) with a Buy rating and a $34 price target as the bank believes the company's RG7128 should become a major drug in the lucrative hepatitis C market.
Click here to read the rest of the article

Analyst Upgrades for March 16th

Posted on 03/16/10 at 8:57am
Analyst Upgrades for 3/16/2010... Alexion (NASDAQ: ALXN) added to Conviction Buy List, $62 target, at Goldman Sachs... BOK Financial (NASDAQ: BOKF) upgraded to Buy, $57 target, at SunTrust...
Click here to read the rest of the article

Pharmasset to Present at Cowen and Company 30th Annual Healthcare Conference

Posted on 03/03/10 at 6:06pm
Pharmasset to Present at Cowen and Company 30th Annual Healthcare Conference PR Newswire PRINCETON, N.J., March 3
Click here to read the rest of the article

Pharmasset Announces Complete Enrollment of RG7128 Phase 2b Clinical Study

Posted on 02/17/10 at 5:15pm
Pharmasset Announces Complete Enrollment of RG7128 Phase 2b Clinical Study - Roche Initiating Additional Clinical Studies with RG7128 - INFORM Studies Delayed PR Newswire PRINCETON, N.J., Feb. 17
Click here to read the rest of the article

Pharmasset Reports Fiscal First Quarter 2010 Financial Results

Posted on 02/09/10 at 5:00pm
PRINCETON, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
Click here to read the rest of the article